12:07 PM EST, 02/25/2026 (MT Newswires) -- Longeveron ( LGVN ) shares were down over 7% in recent Wednesday trading after it announced the results of its phase 2b clinical trial evaluating its laromestrocel stem cell therapy in patients with age-related frailty.

The study found that compared with placebo, its intravenous laromestrocel stem cell product improved the physical condition of patients with age-related clinical frailty after nine months, the company said.

Patients treated with laromestrocel demonstrated clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo, the company said.

Longeveron ( LGVN ) said that its findings highlight a possible stem cell therapy approach for patients with hypomobility and other features of aging frailty.

Price: 0.53, Change: -0.05, Percent Change: -8.48